Press Releases - Cardiol Therapeutics

Investor Resources

Contact Us

Investor ResourcesPress Releases

Press Releases

Cardiol Therapeutics’ Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

November 18, 2024

Cardiol Therapeutics to Advance CardiolRx™ into a Late-stage Trial in Patients with Recurrent Pericarditis

October 22, 2024

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

October 11, 2024

Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares

October 10, 2024

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

October 9, 2024

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

October 8, 2024

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx™ for Acute Myocarditis

September 24, 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

September 10, 2024

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

June 27, 2024